Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Amphastar Pharmaceuticals stock | $18.89

Own Amphastar Pharmaceuticals stock in just a few minutes.

Fact checked

Amphastar Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Amphastar Pharmaceuticals shares (AMPH) are listed on the NASDAQ and all prices are listed in US Dollars. Amphastar Pharmaceuticals employs 2,027 staff and has a trailing 12-month revenue of around USD$337.3 million.

How to buy shares in Amphastar Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Amphastar Pharmaceuticals. Find the stock by name or ticker symbol: AMPH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Amphastar Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$18.89, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Amphastar Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Amphastar Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Amphastar Pharmaceuticals share price

Use our graph to track the performance of AMPH stocks over time.

Amphastar Pharmaceuticals shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$18.89
52-week rangeUSD$12.325 - USD$22.69
50-day moving average USD$18.6973
200-day moving average USD$19.9159
Wall St. target priceUSD$22.2
PE ratio 141.7778
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.135

Buy Amphastar Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Amphastar Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Amphastar Pharmaceuticals price performance over time

Historical closes compared with the close of $18.89 from 2020-12-09

1 week (2021-01-13) -2.58%
1 month (2020-12-18) -0.37%
3 months (2020-10-20) -8.43%
6 months (2020-07-20) -9.75%
1 year (2020-01-17) -5.93%
2 years (2019-01-18) -13.90%
3 years (2018-01-19) 19.37
5 years (2016-01-20) 50.88%

Is Amphastar Pharmaceuticals under- or over-valued?

Valuing Amphastar Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amphastar Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Amphastar Pharmaceuticals's P/E ratio

Amphastar Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 142x. In other words, Amphastar Pharmaceuticals shares trade at around 142x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Amphastar Pharmaceuticals's PEG ratio

Amphastar Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.77. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amphastar Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Amphastar Pharmaceuticals's EBITDA

Amphastar Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$33.3 million.

The EBITDA is a measure of a Amphastar Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Amphastar Pharmaceuticals financials

Revenue TTM USD$337.3 million
Operating margin TTM 3.77%
Gross profit TTM USD$131.9 million
Return on assets TTM 1.33%
Return on equity TTM 1.73%
Profit margin 1.97%
Book value $8.525
Market capitalisation USD$909.2 million

TTM: trailing 12 months

Shorting Amphastar Pharmaceuticals shares

There are currently 2.6 million Amphastar Pharmaceuticals shares held short by investors – that's known as Amphastar Pharmaceuticals's "short interest". This figure is 3.5% down from 2.7 million last month.

There are a few different ways that this level of interest in shorting Amphastar Pharmaceuticals shares can be evaluated.

Amphastar Pharmaceuticals's "short interest ratio" (SIR)

Amphastar Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Amphastar Pharmaceuticals shares currently shorted divided by the average quantity of Amphastar Pharmaceuticals shares traded daily (recently around 221608.34049871). Amphastar Pharmaceuticals's SIR currently stands at 11.63. In other words for every 100,000 Amphastar Pharmaceuticals shares traded daily on the market, roughly 11630 shares are currently held short.

However Amphastar Pharmaceuticals's short interest can also be evaluated against the total number of Amphastar Pharmaceuticals shares, or, against the total number of tradable Amphastar Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amphastar Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Amphastar Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0851% of the tradable shares (for every 100,000 tradable Amphastar Pharmaceuticals shares, roughly 85 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Amphastar Pharmaceuticals.

Find out more about how you can short Amphastar Pharmaceuticals stock.

Amphastar Pharmaceuticals share dividends

We're not expecting Amphastar Pharmaceuticals to pay a dividend over the next 12 months.

Amphastar Pharmaceuticals share price volatility

Over the last 12 months, Amphastar Pharmaceuticals's shares have ranged in value from as little as $12.325 up to $22.69. A popular way to gauge a stock's volatility is its "beta".

AMPH.US volatility(beta: 0.86)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amphastar Pharmaceuticals's is 0.8588. This would suggest that Amphastar Pharmaceuticals's shares are less volatile than average (for this exchange).

Amphastar Pharmaceuticals overview

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; lidocaine jelly, a local anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection for newborn babies; atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; morphine injection; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as recombinant human insulin API (active pharmaceutical ingredients) and porcine insulin API. Further, the company has a pipeline of 20 product candidates in various stages of development for various indications. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site